![Christopher A. Bamford](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher A. Bamford
No más puestos en curso
Perfil
Christopher A.
Bamford is Head of Development for NovaBiotics Ltd.
and a Post-Doctoral Scientist at the Harvard Medical School.
He has biotech research management experience.
Dr. Bamford holds a PhD degree.
Antiguos cargos conocidos de Christopher A. Bamford.
Empresas | Cargo | Fin |
---|---|---|
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Christopher A. Bamford